

PSHCP Submission & eligibility guidelines for compounds



This compound submission and eligibility guidelines is for the Public Service Health Care Plan (PSHCP).

Ineligible compounds

- The product is for cosmetic use
- The product contains an ineligible base (see list below for ineligible bases)
- The product contains an ineligible ingredient (see list below for ineligible ingredients).

Ineligible bases and ingredients: The following chemicals/drugs are not eligible for reimbursement by the PSHCP plan, even if combined with a prescription-requiring medication or with a product considered to be an eligible benefit.

Ineligible bases (In addition, all bases with an SPF rating are deemed ineligible)		
Alpha hydroxy acid	Formula 405	Ombrelle product line
Alpha hydroxy serum	GlyDerm	Pond's product line
Aminophylline thigh cream	Glyquin	Porcelana
Aveeno skin brightening	Hyaluronic acid complex cream	Rejuva
Aveeno SPF products	Kinerase	Renova
Avene product line	La Roche Posay product line	Reversa product line
Benoquin (Monobenzone) (Benzoquin)	Lubriderm SPF products	Skinceutical product line
Biobase-G	Lustra product line	Solage
Biotherm product line	M.D. Forte	Solaquin
Dermophil lotion	Marcelle product line	Ultraquin
Dilusol AHA	NeoStrata product line	Vichy product line
Dormer 211 SPF	Neutrogena product line	Viquin Forte
Eldopaque	Nivea product line	Vitamin E base
Eldoquin	Noxzema product line	

Ineligible ingredients		
Chlorohydroquinone	Lipoic acid	Topical triamcinolone (when mixed with distilled water & alcohol)
Glycolic acid	Mandelic acid	Topical vitamin K
Hydroquinone	Retinol	Yohimbine
Kojic acid	Titanium dioxide	Acetyl mandelic acid
Minoxidil	Hyaluronic acid/ sodium hyaluronate	

Eligible compounds

Compounds are eligible if the medicinal ingredient is covered by the PSHCP plan.

Important: Even though an eligible prescription requiring DIN/PIN may be accepted online, if it has been added to a compound containing an ineligible ingredient or base, the compound will be deemed ineligible and charge backs will apply.

Comprehensive TELUS Health compound PINs for PSHCP

PIN	Full name	Complete eligibility criteria (primary medicinal ingredient)
00991186	Topical salicylic acid (40% or greater)	Concentrations 40% or greater
00991187	Topical antibiotics	Clindamycin Erythromycin Metronidazole Neomycin Amikacin Cefazolin Vancomycin Gentamycin Tobramycin
00991188	Compounded corticosteroid	Hydrocortisone (greater than 1%) Betamethasone Clobetasol Desonide Dexamethasone Triamcinolone
00991189	Compounded fertility treatment	Clomiphene citrate Metformin Progesterone (if suppository – PIN 00990054)
00990054	Compounded fertility treatment – progesterone suppositories	Progesterone suppositories
00991190	Compounded skin treatments	Containing coal tar/LCD (10% or greater) Sulfur (8% or greater) Doxepin Lactic acid (>17%) Methchloroethamine Sucralfate Sulfacetamide Thiabendazole Urea Verapamil
00991191	Topical pain treatments (with or without narcotic)	Phenytoin Gabapentin Clonidine Amitriptyline Amantadine Cyclobenzaprine Baclofen Pregabalin
00991192	Topical pain treatments (narcotic primary ingredient)	Morphine Oxycodone Methadone Codeine
00991193	Compounded antifungal	Ciclopirox Itraconazole Ketoconazole Clotrimazole Nystatin Miconazole
00991194	Intranasal compounds	Hydroxycobalamin Mupirocin Oxytocin Wilson's solution (gentamycin in saline) Methylprednisolone

00991195	Compounded suppositories	Diazepam Codeine Morphine Baclofen
00991196	Wart treatment	Cantharidin (>0.7%)
00991197	Other eligible compounds	Diltiazem Nifedipine Glutaraldehyde (10% or greater) Dimercaprol Folic acid (>1mg) Phenazopyridine Disulfiram Demeclocycline Acetyl-L-carnitine, comoglicic acid (>2%) Magic mouthwash Neomycin
Call pharmacy support centre	Backorder – compounding	To be used when compounding a commercially available product when it is on back order. The DIN of the commercially available product must be a benefit on the members plan in order to compound it in the case of a backorder. Documentation of the backorder must be kept on file.
00999984	Topical nsaid	Diclofenac Ibuprofen Indomethacin Ketoprofen Naproxen Meloxicam Piroxicam Celecoxib Flurbiprofen
00900669	Invasive erectile dysfunction (bimix/trimix)	Papaverine (+/- prostaglandin) Phentolamine (+/- prostaglandin)
90800233	Hormone replacement therapy – progesterone	Progesterone for HRT
00990111	Hormone replacement therapy – estrogen	Estrogen (estriol/estrone/estradiol) for HRT
90800234	Hormone replacement therapy – testosterone	Testosterone for HRT
Call pharmacy support centre	Compound not eligible for provincial COB	To be used for compound claims which are eligible benefits under the TELUS Health compounding policy but which do not qualify under the provincial plan. Documentation must be kept on file with rationale of why this compound is NOT covered by the provincial plan but is eligible under the TELUS compound policy.
Call pharmacy support centre	Custom dose compounds (using raw ingredients)	Example: fluoxetine, omeprazole, naltrexone, T3/T4 liothyronine/levothyroxine, desiccated thyroid. Please note, the above are examples only and not the exhaustive list of eligible ingredients. Eligibility will be based on coverage of the commercially available strength. Please call the TELUS Health Assure Claims pharmacy support centre to verify eligibility of the commercially available strength.

As a reminder, all PSHCP compound claims must be billed entirely through the online Assure system and whenever possible, we require that you transmit compound claims using the DIN of an active medicinal ingredient in that compound (if applicable). This will ensure an online eligibility check of the DIN/PIN you have transmitted.



Visit us at telushealth.com

TELUS is a registered trademark of TELUS Corporation and is used under license.
All other trademarks are the property of their respective owners.

© 2022 TELUS

